You are here

Print

The Synergy Lyon Cancer Foundation is an actor in IMODI

Platforms

The Synergy Lyon Cancer Foundation and its technological facilities are investing in the national project, IMODI (Innovative MODels Initiative).

The Synergy Lyon Cancer Foundation and its technological facilities are investing in the national project, IMODI (Innovative MODels Initiative).

Managed by Oncodesign, the Innovative MODels Initiative (IMODI) is a national project and winner of the Investments for the Future Program, which gathers academic institutions (national research institutes, universities and hospitals) and private companies (pharmaceutical laboratories and SMBs in biotechnology). These partners share the objective of setting up a national sector for developing cancer prediction models, by grafting tumours into mice, thus offering preclinical models dedicated to personalised therapy.

Of the 8 cancers included in the scope of the project, the Léon Bérard Centre will be involved in the development of models and therefore the collection of samples and associated clinical data of breast and ovarian cancers. It will also carry out the histological and molecular characterisation of biological samples and in-vivo models.

The Synergy Lyon Cancer Foundation will also play a central role in the IMODI project:

  • by performing xenografts at the Tumour Models Laboratory,
  • and by the bioinformatics processing of data obtained from molecular analyses.